Collegium Pharmaceutical Inc

COLL

Add to Watchlist

33.780USD

-1.050-3.01%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Collegium Pharmaceutical Inc's Score

Industry at a Glance

Industry Ranking

12 / 155

Overall Ranking

47 / 4482

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Collegium Pharmaceutical Inc Highlights

StrengthsRisks

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 37.72% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 780.57M.

Fairly Valued

The company’s latest PE is 14.32, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 38.69M shares, decreasing 9.82% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 17.18K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

54.333

Target Price

+55.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Collegium Pharmaceutical Inc is 8.89, ranking 22 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 193.52M, representing a year-over-year increase of 8.87%, while its net profit experienced a year-over-year increase of 499.75%.

Score

Industry at a Glance

Previous score

8.89

Change

0



Financials

6.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.81

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Collegium Pharmaceutical Inc is 8.57, ranking 14 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 14.32, which is 728.22% below the recent high of 118.62 and 617.45% above the recent low of -74.11.

Score

Industry at a Glance

Previous score

8.57

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/155

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Collegium Pharmaceutical Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 48.00, with a high of 58.00 and a low of 44.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Collegium Pharmaceutical Inc is 7.05, ranking 57 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 38.90 and the support level at 30.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.25

Change

-0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Collegium Pharmaceutical Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 119.28%, representing a quarter-over-quarter decrease of 6.89%. The largest institutional shareholder is James Simons, holding a total of 1.47M shares, representing 4.53% of shares outstanding, with 9.89% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

4.48M

-1.57%

Eventide Asset Management, LLC

1.88M

-21.53%

Renaissance Technologies LLC

Star Investors

1.62M

+1.14%

Fuller & Thaler Asset Management Inc.

1.50M

-0.17%

Rubric Capital Management LP

1.50M

-47.06%

Janus Henderson Investors

1.45M

+59.14%

MFS Investment Management

1.31M

+65.34%

State Street Investment Management (US)

1.31M

+1.29%

Principal Global Investors (Equity)

1.31M

+0.30%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Collegium Pharmaceutical Inc is 7.30, ranking 38 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Collegium Pharmaceutical Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Collegium Pharmaceutical Inc

COLL

8.25 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

9.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment